These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30345152)

  • 1. Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.
    Eguchi A; Feldstein AE
    Liver Res; 2018 Mar; 2(1):30-34. PubMed ID: 30345152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis.
    Povero D; Feldstein AE
    Diabetes Metab J; 2016 Feb; 40(1):1-11. PubMed ID: 26912150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets.
    Eguchi A; Iwasa M; Nakagawa H
    Liver Int; 2023 Feb; 43(2):292-298. PubMed ID: 36462157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease.
    Newman LA; Sorich MJ; Rowland A
    J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32610455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH-Future Horizons in NASH Management.
    Trifylli EM; Kriebardis AG; Koustas E; Papadopoulos N; Deutsch M; Aloizos G; Fortis SP; Papageorgiou EG; Tsagarakis A; Manolakopoulos S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis.
    Zhu Q; Li H; Ao Z; Xu H; Luo J; Kaurich C; Yang R; Zhu PW; Chen SD; Wang XD; Tang LJ; Li G; Huang OY; Zheng MH; Li HP; Liu F
    J Nanobiotechnology; 2022 Jul; 20(1):349. PubMed ID: 35897102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease.
    Ban LA; Shackel NA; McLennan SV
    Int J Mol Sci; 2016 Mar; 17(3):376. PubMed ID: 26985892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy.
    Hernández A; Arab JP; Reyes D; Lapitz A; Moshage H; Bañales JM; Arrese M
    Cells; 2020 Mar; 9(4):. PubMed ID: 32231001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological mechanisms and therapeutic targets of fatty liver diseases.
    Wang H; Mehal W; Nagy LE; Rotman Y
    Cell Mol Immunol; 2021 Jan; 18(1):73-91. PubMed ID: 33268887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.
    Eguchi A; Lazaro RG; Wang J; Kim J; Povero D; Willliams B; Ho SB; Stärkel P; Schnabl B; Ohno-Machado L; Tsukamoto H; Feldstein AE
    Hepatology; 2017 Feb; 65(2):475-490. PubMed ID: 27639178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASH and NASH.
    Scaglioni F; Ciccia S; Marino M; Bedogni G; Bellentani S
    Dig Dis; 2011; 29(2):202-10. PubMed ID: 21734385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases.
    Shabangu CS; Huang JF; Hsiao HH; Yu ML; Chuang WL; Wang SC
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease.
    Wu D; Zhu H; Wang H
    Front Physiol; 2021; 12():707429. PubMed ID: 34335310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.
    Hashimoto E; Tokushige K; Ludwig J
    Hepatol Res; 2015 Jan; 45(1):20-8. PubMed ID: 24661406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; Ji P; French B; Tillman B; French SW
    Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.